(USPH) US Physicalrapy - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US90337L1089

USPH: Physical, Therapy, Rehabilitation, Injury, Prevention, Services

U.S. Physical Therapy, Inc. (NYSE: USPH) is a leading operator of outpatient physical therapy clinics, with a strong presence in the healthcare services sector. Founded in 1990 and headquartered in Houston, Texas, the company has built a robust platform across two core segments: Physical Therapy Operations and Industrial Injury Prevention Services. This dual focus allows USPH to address both clinical and preventive care needs, making it a comprehensive player in the physical therapy space.

The Physical Therapy Operations segment is the backbone of USPHs business, providing essential services such as pre- and post-operative care, treatment for orthopedic and sports-related injuries, and rehabilitation for neurological disorders. These services are delivered through a network of outpatient clinics, strategically positioned to serve patients in need of specialized care. The companys clinical expertise is complemented by a data-driven approach to patient outcomes, ensuring high-quality, evidence-based care.

Where USPH truly differentiates itself is through its Industrial Injury Prevention Services. This segment targets employers and insurers, offering a suite of solutions designed to reduce workplace injuries and improve employee performance. Services include onsite injury prevention, ergonomic assessments, and functional capacity evaluations, all delivered by certified physical therapists and athletic trainers. By helping Fortune 500 companies and other clients minimize workplace injuries, USPH not only generates recurring revenue but also builds long-term partnerships with its clients.

From a financial perspective, U.S. Physical Therapy operates with a resilient business model. The company has a market capitalization of approximately $1.3 billion, with a trailing P/E ratio of 98.89, reflecting investor confidence in its growth prospects. The forward P/E ratio of 34.48 suggests expectations for continued expansion. With a price-to-book ratio of 2.72 and a price-to-sales ratio of 2.06, USPH is valued at a premium, indicating its strong market position and operational efficiency.

For investors and fund managers, USPH offers a unique combination of stability and growth. Its diversified revenue streams—spanning clinical care and industrial services—provide a balanced risk profile. The companys focus on preventative care and workplace safety aligns with broader healthcare trends, making it an attractive option for those seeking exposure to the outpatient physical therapy sector. However, the high P/E multiple underscores the importance of closely monitoring the companys ability to sustain its growth trajectory and maintain profitability in

Additional Sources for USPH Stock

USPH Stock Overview

Market Cap in USD 1,019m
Sector Healthcare
Industry Medical Care Facilities
GiC Sub-Industry Health Care Facilities
IPO / Inception 1992-05-28

USPH Stock Ratings

Growth 5y -17.0%
Fundamental 26.4%
Dividend 65.6%
Rel. Strength -35.2
Analysts 4.14/5
Fair Price Momentum 57.76 USD
Fair Price DCF 91.08 USD

USPH Dividends

Dividend Yield 12m 2.30%
Yield on Cost 5y 2.62%
Annual Growth 5y 40.63%
Payout Consistency 92.0%

USPH Growth Ratios

Growth Correlation 3m -93.6%
Growth Correlation 12m -64.8%
Growth Correlation 5y -6.5%
CAGR 5y -0.74%
CAGR/Max DD 5y -0.01
Sharpe Ratio 12m -2.07
Alpha -33.53
Beta 1.508
Volatility 30.79%
Current Volume 208k
Average Volume 20d 97.2k
What is the price of USPH stocks?
As of April 08, 2025, the stock is trading at USD 65.08 with a total of 208,044 shares traded.
Over the past week, the price has changed by -10.06%, over one month by -19.02%, over three months by -25.97% and over the past year by -37.96%.
Is US Physicalrapy a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, US Physicalrapy is currently (April 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 26.35 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of USPH as of April 2025 is 57.76. This means that USPH is currently overvalued and has a potential downside of -11.25%.
Is USPH a buy, sell or hold?
US Physicalrapy has received a consensus analysts rating of 4.14. Therefor, it is recommend to buy USPH.
  • Strong Buy: 2
  • Buy: 4
  • Hold: 1
  • Sell: 0
  • Strong Sell: 0
What are the forecast for USPH stock price target?
According to ValueRays Forecast Model, USPH US Physicalrapy will be worth about 64.5 in April 2026. The stock is currently trading at 65.08. This means that the stock has a potential downside of -0.89%.
Issuer Forecast Upside
Wallstreet Target Price 108.3 66.5%
Analysts Target Price 111.3 71.1%
ValueRay Target Price 64.5 -0.9%